Task order: preventing lung cancer by targeting activated STAT3
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $779,932
Award facts
- Opportunity
- Contract value 100% obligated
- $779,932.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $779,932 |
About this award
The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in preventing lung cancer by targeting activated STAT3. No set-aside designation was specified for this award. The PREVENT program encompasses three pools of preclinical services focused on efficacy, product development, and toxicology testing to advance candidate therapies. ICR will utilize the delivery order funding to provide research and analytical services under Pool 1, Preclinical Efficacy and Biomarkers. This award represents a task order under the PREVENT master IDIQ and supports the National Cancer Institute's efforts to prevent cancer through preclinical drug development.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 21, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $779,932 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award